Oclacitinib

Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively). It is selective for JAK kinases over a panel of 38 additional kinases at 1 µM. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-alpha levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner. Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1beta, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.Formal Name: trans-N-methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide. CAS Number: 1208319-26-9. Synonyms: PF-03394197. Molecular Formula: C15H23N5O2S. Formula Weight: 337.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 14 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 12 mg/ml. lambdamax: 217, 286 nm. SMILES: CNS(C[C@@H]1CC[C@@H](N(C2=NC=NC3=C2C=CN3)C)CC1)(=O)=O. InChi Code: InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-. InChi Key: HJWLJNBZVZDLAQ-HAQNSBGRSA-N.